Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences Limited submitted its unaudited financial results for the quarter ended June 30, 2025, reviewed by Deloitte Haskins & Sells LLP with an unqualified limited review report. On a consolidated basis, revenue from operations rose about 5.9% year-on-year to Rs 65,737 million and net profit was Rs 14,668 million (up roughly 3.3% from Rs 14,199 million), with no exceptional items in the quarter. On a standalone basis, however, revenue fell sharply to Rs 25,883 million from Rs 41,602 million (down ~37.8%) and net profit dropped to Rs 3,847 million from Rs 17,008 million (down ~77%), indicating that consolidated growth was driven by subsidiaries while the parent's core domestic business weakened. Post-quarter, on July 29, 2025, Zydus completed the acquisition of an 85.6% stake in France-based Amplitude Surgical SA for about Euro 256.80 million (~Rs 23,798 million), expanding its medtech footprint.
Consolidated results are only marginally better, but the steep standalone decline is a red flag for the parent's underlying business. The just-completed Amplitude Surgical acquisition adds meaningful medtech scale and could be a future growth driver, but it also brings integration and leverage risks that investors should watch in coming quarters.